ArticleRheumatology international2013
Association of interleukin-18 and systemic lupus erythematosus.
Article in Rheumatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Interleukin 18 (-137G/C, -607C/A) Polymorphisms as Genetic Biomarkers of Susceptibility to Systematic Lupus Erythematosus.Current rheumatology reviews · 2025Article
- Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis.International journal of molecular sciences · 2023Article
- Elevated serum interleukin-34 level in juvenile systemic lupus erythematosus and disease activity.Clinical rheumatology · 2020Article
- Programmed Cell Death Pathways in the Pathogenesis of Systemic Lupus Erythematosus.Journal of immunology research · 2019Review
- Elevated serum levels of interleukin-1β and interleukin-33 in patients with systemic sclerosis in Chinese population.Zeitschrift fur Rheumatologie · 2018Article
- Elevated Serum Interleukin-34 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity.Scientific reports · 2018Article
- Extremely elevated IL-18 levels may help distinguish systemic-onset juvenile idiopathic arthritis from other febrile diseases.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Article
- Article
- Potential roles of nucleotide-binding oligomerization domain 2 in the pathogenesis of systemic lupus erythematosus.Rheumatology international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-18 (IL-18), belongs to the IL-1 cytokine family, has a variety of effects on dendritic cell, T cell, natural killer cell. Previous studies have identified that IL-18 was associated with the pathogenesis of systemic lupus erythematosus (SLE), wherein elevated expression of IL-18 was found in the serum of patients, and IL-18 polymorphisms with susceptibility to SLE were reported, suggesting that IL-18 may be therapeutically relevant to SLE. In this article, we will discuss the role of IL-18 in the pathogenesis of and its therapeutic potential in SLE based on current understandings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.